Department of Emergency and Critical Care Medicine, Wakayama Medical University, Wakayama City, Wakayama, Japan; Department of Infection Prevention and Control, Wakayama Medical University, Wakayama City, Wakayama, Japan.
Department of Infection Prevention and Control, Wakayama Medical University, Wakayama City, Wakayama, Japan.
J Infect Chemother. 2022 Jan;28(1):99-102. doi: 10.1016/j.jiac.2021.09.014. Epub 2021 Oct 2.
Multisystem inflammatory syndrome in adults (MIS-A) is a rare and emerging syndrome after coronavirus disease 2019 (COVID-19). To the best of our knowledge, Japanese cases of MIS-A are rarely reported. Here, we describe a case of MIS-A in a 44-year-old Japanese woman presenting with multiorgan dysfunction (i.e., cardiovascular and mucocutaneous involvement) and markedly elevated inflammatory markers 2 weeks after recovery from COVID-19. Treatment with intravenous immunoglobulins and corticosteroids resolved her symptoms. On the 13th day, she was discharged from the hospital with no recurrences on follow-up. This study highlights the importance of recognizing this emerging syndrome when treating patients with multiorgan dysfunction after COVID-19.
成人多系统炎症综合征（MIS-A）是 COVID-19 后一种罕见且新兴的综合征。据我们所知，日本的 MIS-A 病例很少见。在这里，我们描述了一例 44 岁日本女性的 MIS-A 病例，她在 COVID-19 康复后 2 周出现多器官功能障碍（即心血管和黏膜皮肤受累）和明显升高的炎症标志物。静脉注射免疫球蛋白和皮质类固醇治疗缓解了她的症状。第 13 天，她出院，随访期间无复发。本研究强调了在 COVID-19 后治疗多器官功能障碍患者时识别这种新兴综合征的重要性。
